Johnson & Johnson $JNJ Shares Acquired by Dynamic Advisor Solutions LLC

Key Points

• Dynamic Advisor Solutions LLC increased its holdings in Johnson & Johnson by 5.1%, owning 51,196 shares valued at $7.82 million as of the most recent SEC filing.
• Johnson & Johnson reported earnings per share of $2.77 for the last quarter, exceeding estimates and showing a revenue increase of 5.8% year-over-year.
• The company announced a quarterly dividend of $1.30, which results in an annual dividend yield of 2.9%, with a payout ratio of 55.61%.

Dynamic Advisor Solutions LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 51,196 shares of the company's stock after buying an additional 2,507 shares during the quarter. Dynamic Advisor Solutions LLC's holdings in Johnson & Johnson were worth $7,820,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Lantz Financial LLC lifted its position in Johnson & Johnson by 3.3% in the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock valued at $1,986,000 after purchasing an additional 377 shares during the period. Apexium Financial LP lifted its position in Johnson & Johnson by 10.7% in the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after purchasing an additional 2,310 shares during the period. Joel Isaacson & Co. LLC lifted its position in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after purchasing an additional 2,526 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its position in Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company's stock valued at $12,164,000 after purchasing an additional 4,816 shares during the period. Finally, Range Financial Group LLC lifted its position in Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock valued at $2,635,000 after purchasing an additional 2,529 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Up 1.0%

NYSE:JNJ traded up $1.81 during mid-day trading on Friday, hitting $175.97. The company had a trading volume of 25,617,065 shares, compared to its average volume of 6,995,150. The business has a fifty day simple moving average of $172.80 and a 200-day simple moving average of $161.67. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $181.16. The firm has a market capitalization of $423.80 billion, a price-to-earnings ratio of 18.82, a PEG ratio of 2.24 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The company had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.0%. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JNJ shares. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays lifted their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. lifted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "neutral" rating in a research report on Tuesday, September 16th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Finally, Guggenheim reiterated a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $177.87.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.